Literature DB >> 3556441

Epidemiological studies on leptospirosis in Chiang Mai (Thailand).

Y Arimitsu, S Kobayashi, T Matuhasi, H Suzuki, Y Yamaji, S Suprasert, J Supawadee.   

Abstract

A total of 270 serum samples collected in Chiang Mai province were examined for antibodies against leptospira using the microscopic agglutination test (MAT). Four of 40 serum specimens from patients who visited the hospital with the common cold, were positive with a titre of 20. Twelve (10.4%) of the 115 samples in the Doi Saket district showed a positive reaction. Only 2 of 115 sera of school children in Chiang Mai city had antibodies. Specific serovars detected were Leptospira hebdomadis (5), L. australis (3), L. icterohaemorrhagiae (2), L. bataviae (2), and one each of L. canicola, L. javanica and L. pyrogenes. One case of mixed infection with L. hebdomadis and L. javanica, and L. autumnalis and L. australis were observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556441      PMCID: PMC2235281          DOI: 10.1017/s0950268800061756

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  2 in total

1.  APPLICATION OF A MICROTECHNIQUE TO THE AGGLUTINATION TEST FOR LEPTOSPIRAL ANTIBODIES.

Authors:  M M GALTON; C R SULZER; C A SANTAROSA; M J FIELDS
Journal:  Appl Microbiol       Date:  1965-01

2.  Leptospirosis in Trinidad and Grenada, with special reference to the mongoose.

Authors:  C O Everard; A E Green; J W Glosser
Journal:  Trans R Soc Trop Med Hyg       Date:  1976       Impact factor: 2.184

  2 in total
  2 in total

1.  Occupational hazard of unnoticed leptospirosis in water ways maintenance staff.

Authors:  G Andre-Fontaine; X Peslerbe; J P Ganiere
Journal:  Eur J Epidemiol       Date:  1992-03       Impact factor: 8.082

2.  Travel-related leptospirosis in Israel: a nationwide study.

Authors:  Eyal Leshem; Gadi Segal; Ada Barnea; Shmuel Yitzhaki; Iris Ostfeld; Silvio Pitlik; Eli Schwartz
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.